In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turing Pharmaceuticals AG

www.turingpharma.com

Latest From Turing Pharmaceuticals AG

FDA Approves First Generic Of Daraprim

Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.

Generic Drugs Approvals

The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

Pricing Debate Enforcement

Pharma Enforcement Remains 'Priority Area' In FTC's 2021 Budget Request

US Federal Trade Commission has mainly focused in pay-for-delay cases over the past decade, but pricing strategies are an emerging area of attention; industry is paying close attention to potential enforcement in biosimilar market.

Enforcement Legal Issues

Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions

In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.

Legal Issues Pricing Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Turing Pharmaceuticals LLC
  • Turing Pharmaceuticals LLC
  • Turing Pharmaceuticals LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Turing Pharmaceuticals AG
  • Senior Management
  • Ron Tilles, Interim CEO
    Nancy Retzlaff, Chief Commercial Officer
    Eliseo Oreste Salinas, MD, Pres., R&D
  • Contact Info
  • Turing Pharmaceuticals AG
    Phone: 41 760 24 24
    Haldenstrasse 5
    Baar, NY CH-6340
    Switzerland
UsernamePublicRestriction

Register